Do analysts prefer BJDX or NDRA?

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 463.06%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, BJDX or NDRA?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A ENDRA Life Sciences N/A N/A -$7.03M -$8.15 N/A

Is BJDX or NDRA more profitable?

Bluejay Diagnostics' return on equity of -144.27% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% ENDRA Life Sciences N/A -433.64% -204.58%

Do analysts rate PAVM or BJDX?

PAVmed presently has a consensus price target of $56.00, suggesting a potential upside of 1,112.12%. Given PAVmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe PAVmed is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PAVM or BJDX more profitable?

Bluejay Diagnostics has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Bluejay Diagnostics' return on equity of -144.27% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -21,914.12% -146.19% -18.39% Bluejay Diagnostics N/A -144.27% -115.00%

Do analysts recommend SONX or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VVOS or BJDX?

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 781.33%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend INBS or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Bluejay Diagnostics (BJDX) Competitors

$0.99 -0.08 (-7.74%)

As of 04:00 PM Eastern

Compare

BJDX vs. NDRA, PAVM, SONX, VVOS, and INBS

Should you buy Bluejay Diagnostics stock or one of its competitors? Bluejay Diagnostics's main competitors and comparable companies include ENDRA Life Sciences (NDRA), PAVmed (PAVM), Sonendo (SONX), Vivos Therapeutics (VVOS), and Intelligent Bio Solutions (INBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

Bluejay Diagnostics (NASDAQ:BJDX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 463.06%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Bluejay Diagnostics. ENDRA Life Sciences' average media sentiment score of 2.00 beat Bluejay Diagnostics' score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
ENDRA Life Sciences	Very Positive

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$8.15	N/A

Bluejay Diagnostics' return on equity of -144.27% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
ENDRA Life Sciences	N/A	-433.64%	-204.58%

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bluejay Diagnostics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

Summary

ENDRA Life Sciences beats Bluejay Diagnostics on 7 of the 13 factors compared between the two stocks.

How does Bluejay Diagnostics compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PAVmed has higher revenue and earnings than Bluejay Diagnostics. PAVmed is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	66.00	$400K	-$37.40	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

In the previous week, PAVmed had 3 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 3 mentions for PAVmed and 0 mentions for Bluejay Diagnostics. PAVmed's average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.

Company	Overall Sentiment
PAVmed	Neutral
Bluejay Diagnostics	Neutral

Bluejay Diagnostics has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Bluejay Diagnostics' return on equity of -144.27% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

PAVmed presently has a consensus price target of $56.00, suggesting a potential upside of 1,112.12%. Given PAVmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe PAVmed is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PAVmed has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Summary

PAVmed beats Bluejay Diagnostics on 9 of the 14 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Sonendo?

Sonendo (NYSE:SONX) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Sonendo's average media sentiment score of 0.00 equaled Bluejay Diagnostics'average media sentiment score.

Company	Overall Sentiment
Sonendo	Neutral
Bluejay Diagnostics	Neutral

Sonendo has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Bluejay Diagnostics has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Bluejay Diagnostics' return on equity of -144.27% beat Sonendo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Bluejay Diagnostics has lower revenue, but higher earnings than Sonendo. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.11	-$60.92M	-$71.12	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

28.7% of Sonendo shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 7.9% of Sonendo shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sonendo beats Bluejay Diagnostics on 6 of the 11 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vivos Therapeutics has a beta of 6.22, indicating that its stock price is 522% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 781.33%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vivos Therapeutics had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 2 mentions for Vivos Therapeutics and 0 mentions for Bluejay Diagnostics. Vivos Therapeutics' average media sentiment score of 0.74 beat Bluejay Diagnostics' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Positive
Bluejay Diagnostics	Neutral

Bluejay Diagnostics has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Bluejay Diagnostics' return on equity of -144.27% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

Bluejay Diagnostics has lower revenue, but higher earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.25	-$21.17M	-$2.14	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Summary

Vivos Therapeutics beats Bluejay Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Bluejay Diagnostics compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Bluejay Diagnostics has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -296.73%. Bluejay Diagnostics' return on equity of -144.27% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-296.73%	-176.09%	-89.71%
Bluejay Diagnostics	N/A	-144.27%	-115.00%

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bluejay Diagnostics has lower revenue, but higher earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$3.05M	1.54	-$10.57M	-$12.22	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A

Intelligent Bio Solutions has a beta of 4.21, indicating that its stock price is 321% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Intelligent Bio Solutions had 2 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 2 mentions for Intelligent Bio Solutions and 0 mentions for Bluejay Diagnostics. Intelligent Bio Solutions' average media sentiment score of 0.12 beat Bluejay Diagnostics' score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Intelligent Bio Solutions	Neutral
Bluejay Diagnostics	Neutral

Summary

Intelligent Bio Solutions beats Bluejay Diagnostics on 7 of the 13 factors compared between the two stocks.

Get Bluejay Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BJDX vs. The Competition

Export

Metric	Bluejay Diagnostics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.11M	$5.82B	$7.02B	$12.98B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	-0.08	24.71	269.19	24.72
Price / Sales	N/A	61.03	588.76	97.77
Price / Cash	N/A	33.55	28.89	37.42
Price / Book	0.12	6.21	11.27	6.42
Net Income	-$6.85M	$147.87M	$3.45B	$347.03M
7 Day Performance	4.76%	3.40%	3.56%	2.49%
1 Month Performance	-31.92%	1.66%	-0.58%	-1.04%
1 Year Performance	-82.37%	6.26%	77.52%	23.22%

Bluejay Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BJDX Bluejay Diagnostics	0.6968 of 5 stars	$0.99 -7.7%	N/A	-80.9%	$1.11M	N/A	N/A	9	Gap Down
NDRA ENDRA Life Sciences	3.1572 of 5 stars	$4.47 +5.9%	$25.00 +459.2%	+5.3%	$5.68M	N/A	N/A	20	Positive News Upcoming Earnings
PAVM PAVmed	2.5284 of 5 stars	$5.07 +0.6%	$56.00 +1,004.5%	-65.4%	$5.07M	$70K	N/A	90	Upcoming Earnings
SONX Sonendo	N/A	$1.01 flat	N/A	+4,445.5%	$4.82M	$44.40M	N/A	250	Upcoming Earnings
VVOS Vivos Therapeutics	2.0394 of 5 stars	$0.34 -27.5%	$2.80 +735.8%	-92.6%	$4.67M	$17.44M	N/A	160	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BJDX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. NDRA, PAVM, SONX, VVOS, and INBS

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

Summary

How does Bluejay Diagnostics compare to PAVmed?

Summary

How does Bluejay Diagnostics compare to Sonendo?

Summary

How does Bluejay Diagnostics compare to Vivos Therapeutics?

Summary

How does Bluejay Diagnostics compare to Intelligent Bio Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bluejay Diagnostics (BJDX) Competitors

BJDX vs. NDRA, PAVM, SONX, VVOS, and INBS

How does Bluejay Diagnostics compare to ENDRA Life Sciences?

Do analysts prefer BJDX or NDRA?

Does the media favor BJDX or NDRA?

Which has better valuation and earnings, BJDX or NDRA?

Is BJDX or NDRA more profitable?

Do insiders and institutionals hold more shares of BJDX or NDRA?

Which has more volatility and risk, BJDX or NDRA?

Summary

How does Bluejay Diagnostics compare to PAVmed?

Do institutionals & insiders hold more shares of PAVM or BJDX?

Which has better earnings and valuation, PAVM or BJDX?

Does the media favor PAVM or BJDX?

Is PAVM or BJDX more profitable?

Do analysts rate PAVM or BJDX?

Which has more risk and volatility, PAVM or BJDX?

Summary

How does Bluejay Diagnostics compare to Sonendo?

Does the media favor SONX or BJDX?

Which has more risk & volatility, SONX or BJDX?

Is SONX or BJDX more profitable?

Which has higher valuation and earnings, SONX or BJDX?

Do institutionals and insiders hold more shares of SONX or BJDX?

Do analysts recommend SONX or BJDX?

Summary

How does Bluejay Diagnostics compare to Vivos Therapeutics?

Do insiders and institutionals believe in VVOS or BJDX?

Which has more volatility & risk, VVOS or BJDX?

Do analysts recommend VVOS or BJDX?

Does the media prefer VVOS or BJDX?

Is VVOS or BJDX more profitable?

Which has better valuation & earnings, VVOS or BJDX?

Summary

How does Bluejay Diagnostics compare to Intelligent Bio Solutions?

Is INBS or BJDX more profitable?

Do institutionals & insiders have more ownership in INBS or BJDX?

Which has higher valuation and earnings, INBS or BJDX?

Which has more volatility & risk, INBS or BJDX?

Do analysts recommend INBS or BJDX?

Does the media prefer INBS or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BJDX vs. The Competition

Bluejay Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools